Product Details

Sofosbuvir + Velpatasvir Tablets BP 490 mg deliver a high-quality combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose combination manages chronic hepatitis C virus (HCV) infection, combining pangenotypic direct-acting antiviral action in a single tablet.

The tablets combine:

• Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor that blocks HCV viral RNA replication, and
• Velpatasvir, an NS5A inhibitor that blocks a protein essential for HCV viral replication and assembly.

Doctors commonly prescribe this combination for chronic hepatitis C infection across multiple genotypes, including in patients with or without compensated cirrhosis. Hospitals, clinics, and specialty pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant combination therapy
• Treats chronic hepatitis C (HCV) across multiple genotypes
• Delivers dual direct-acting antiviral (DAA) action
• Accurate 490 mg dosage per tablet
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, specialty clinic, and pharmacy use